Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Sabrina Herrera"'
Autor:
Rachel Schiff, Mothaffar F. Rimawi, C. Kent Osborne, Jenny C. Chang, Gary C. Chamness, Meghana V. Trivedi, Anne C. Pavlick, Sara Lopez-Tarruella, Joe W. Gray, Laura M. Heiser, Nicholas J. Wang, Carmine De Angelis, Susan G. Hilsenbeck, Tao Wang, Carolina Gutierrez, Alejandro Contreras, Sufeng Mao, Sabrina Herrera, Agostina Nardone, Xiaoyong Fu, Yen-Chao Wang, Huizhong Hu, Mario Giuliano
Supplementary Figure 2. ER expression changes upon neoadjuvant treatment with trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b38ed6a099216efbf2e1288834c85f
https://doi.org/10.1158/1078-0432.22456521.v1
https://doi.org/10.1158/1078-0432.22456521.v1
Autor:
Rachel Schiff, Mothaffar F. Rimawi, C. Kent Osborne, Jenny C. Chang, Gary C. Chamness, Meghana V. Trivedi, Anne C. Pavlick, Sara Lopez-Tarruella, Joe W. Gray, Laura M. Heiser, Nicholas J. Wang, Carmine De Angelis, Susan G. Hilsenbeck, Tao Wang, Carolina Gutierrez, Alejandro Contreras, Sufeng Mao, Sabrina Herrera, Agostina Nardone, Xiaoyong Fu, Yen-Chao Wang, Huizhong Hu, Mario Giuliano
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical tumor samples.Experimental desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e0587fb0456056a2d9cbd81adb8b39
https://doi.org/10.1158/1078-0432.c.6523335
https://doi.org/10.1158/1078-0432.c.6523335
Autor:
Rachel Schiff, Mothaffar F. Rimawi, C. Kent Osborne, Jenny C. Chang, Gary C. Chamness, Meghana V. Trivedi, Anne C. Pavlick, Sara Lopez-Tarruella, Joe W. Gray, Laura M. Heiser, Nicholas J. Wang, Carmine De Angelis, Susan G. Hilsenbeck, Tao Wang, Carolina Gutierrez, Alejandro Contreras, Sufeng Mao, Sabrina Herrera, Agostina Nardone, Xiaoyong Fu, Yen-Chao Wang, Huizhong Hu, Mario Giuliano
Supplementary figure legend. Legend of supplementary Figure 1 and 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da5960a0283b1e62e5e00f2e5913808
https://doi.org/10.1158/1078-0432.22456518
https://doi.org/10.1158/1078-0432.22456518
Publikováno v:
Anais Estendidos do XXI Simpósio Brasileiro de Jogos e Entretenimento Digital (SBGames Estendido 2022).
Este estudo apresenta sugestões para o design de uma terapia com exposição à Realidade Virtual. As sugestões foram obtidas a partir de uma avaliação de usuários interagindo com o jogo em RV desenvolvido por [Meireles et al. 2020]. O jogo requ
Publikováno v:
Acta Haematologica
Since the outbreak of the COVID-19 pandemic, much has been learned regarding its clinical course, prognostic inflammatory markers, disease complications, and mechanical ventilation strategy. Clinically, three stages have been identified based on vira
Publikováno v:
Environmental Science and Pollution Research. 27:29688-29696
Azo dyes are extensively used in different industries areas, such as Allura Red (R-40). Previous studies have proven its carcinogenic and mutagenic properties. For the removal of this type of emerging pollutant from effluents, tertiary treatment tech
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Publikováno v:
Modern Pathology
Repositorio Digital Institucional ReDi
Fundación Universitaria de Ciencias de la Salud-FUCS
instacron:Fundación Universitaria de Ciencias de la Salud-FUCS
Repositorio Digital Institucional ReDi
Fundación Universitaria de Ciencias de la Salud-FUCS
instacron:Fundación Universitaria de Ciencias de la Salud-FUCS
Since the outbreak of the COVID-19 pandemic, much has been learned regarding its clinical course, prognostic inflammatory markers, disease complications, and mechanical ventilation strategy. Clinically, three stages have been identified based on vira
Autor:
Sarmistha Nanda, Maria B Hahn, Mario Giuliano, Chad J. Creighton, Laura M. Heiser, Joe W. Gray, Xiaoyong Fu, Carolina Gutierrez, Lanfang Qin, Martin Shea, Rachel Schiff, Nicholas J. Wang, Huizhong Hu, Susan G. Hilsenbeck, Dean P. Edwards, Sabrina Herrera, Sung Yun Jung, Chad A. Shaw, C. Kent Osborne, Gary C. Chamness, Xiaowei Xu
Publikováno v:
Cancer Research. 75:P3-05
Background: The HER2 pathway can be inhibited by potent targeting agents such as lapatinib (L), trastuzumab (T), or their combination (LT), but acquired and de novo resistance still occur. Resistance to these drugs remains a major hurdle in the manag